BUSINESS● LOW2h ago · Sep 12, 2026, 4:57 PM
Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain
Yahoo Finance · global
No summary available — read the full story at the source.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS26m agoInvesting in the Vanguard S&P 500 ETF (VOO)? Beware of This 1 Sneaky Risk.Yahoo FinanceBUSINESS27m agoGCC asks over six lakh property owners to clear ₹847 crore dues by Sept. 30The Hindu